Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Novocure initiates usability study for flexible torso array » 07:32
06/16/21
06/16
07:32
06/16/21
07:32
NVCR

Novocure

$216.59 /

-3.1 (-1.41%)

Novocure announced it has…

Novocure announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clinical sites in Europe. Novocure designed the array to improve patient comfort for all torso and abdominal indications. The new design is intended to improve skin adhesion, to increase degrees-of-motion, and potentially to reduce skin irritation. Novocure plans to conclude the usability study in the third quarter of 2021 and will identify the preferred regulatory pathway to bring the updated, flexible array to patients as soon as possible.

ShowHide Related Items >><<
NVCR Novocure
$216.59 /

-3.1 (-1.41%)

NVCR Novocure
$216.59 /

-3.1 (-1.41%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
NVCR Novocure
$216.59 /

-3.1 (-1.41%)

NVCR Novocure
$216.59 /

-3.1 (-1.41%)

Hot Stocks
Novocure teams with GT Medical on GammaTile therapy in recurrent glioblastoma » 07:35
05/25/21
05/25
07:35
05/25/21
07:35
NVCR

Novocure

$185.25 /

+4.14 (+2.29%)

Novocure announced it…

Novocure announced it has entered into a clinical trial collaboration agreement with GT Medical Technologies, Inc., to develop Tumor Treating Fields TTFields together with GT Medical Technologies' GammaTile Surgically Targeted Radiation Therapy, STaRT, for treatment of recurrent glioblastoma, GBM. Novocure's TTFields are electric fields that disrupt cancer cell division. GammaTile is an FDA-cleared therapy for the treatment of all types of brain tumors. "Our collaboration with GT Medical Technologies is an exciting and important opportunity to test the radio-sensitizing effect of Tumor Treating Fields, which will be applied for at least two weeks prior to resection and GammaTile implantation," said William Doyle, Novocure's Executive Chairman. "This trial is designed to build additional evidence of the effectiveness of Tumor Treating Fields plus radiation therapy and to explore the potential to further extend survival for recurrent GBM patients." Novocure and GT Medical Technologies plan to conduct a phase 2 pilot study to test the effectiveness and safety of neo-adjuvant TTFields followed by resection, GammaTile Therapy, and adjuvant TTFields for recurrent GBM. The study is designed to enroll approximately 55 patients in the United States. Progression free survival for the intent-to-treat population is the primary endpoint of the study. Secondary endpoints include overall survival, PFS for per protocol patients, time to progression, six-month survival rate, one-year survival rate, PFS at six months, and safety.

ShowHide Related Items >><<
NVCR Novocure
$185.25 /

+4.14 (+2.29%)

NVCR Novocure
$185.25 /

+4.14 (+2.29%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
NVCR Novocure
$185.25 /

+4.14 (+2.29%)

NVCR Novocure
$185.25 /

+4.14 (+2.29%)

Over a month ago
Hot Stocks
Zai Lab announces first patient treated in Greater China in METIS Phase 3 trial » 09:25
05/24/21
05/24
09:25
05/24/21
09:25
ZLAB

Zai Lab

$164.51 /

+2.05 (+1.26%)

, NVCR

Novocure

$181.17 /

-1.13 (-0.62%)

Zai Lab Limited (ZLAB)…

Zai Lab Limited (ZLAB) announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Zai's partner NovoCure Limited (NVCR) to study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer. The METIS trial is a pivotal, randomized, controlled Phase 3 trial designed to test the efficacy and safety of TTFields, generated by a medical device, the NovoTTF-100M System, in patients with 1-10 newly diagnosed brain metastasis from NSCLC. TTFields are administered to patients concomitantly with the best standard of care treatments that would normally be used to treat lung cancer. The trial is expected to enroll 270 patients randomized 1:1 to receive, following radiosurgery, either TTFields at a frequency of 150kHz plus supportive care or supportive care alone. The primary endpoint is time to first cerebral progression. Secondary endpoints include, among others, time to neurocognitive failure, overall survival, and radiological response rate.

ShowHide Related Items >><<
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

04/14/21 SVB Leerink
Zai Lab price target raised to $192 from $183 at SVB Leerink
04/13/21 Goldman Sachs
Zai Lab price target raised to $211.23 after LUNAR trial update at Goldman Sachs
04/13/21 Guggenheim
Zai Lab price target raised to $250 from $165 at Guggenheim
02/08/21 Jefferies
Zai Lab price target raised to $225 upon assumption at Jefferies
NVCR Novocure
$181.17 /

-1.13 (-0.62%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

  • 21
    Apr
ZLAB Zai Lab
$164.51 /

+2.05 (+1.26%)

NVCR Novocure
$181.17 /

-1.13 (-0.62%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
05/21/21
05/21
04:55
05/21/21
04:55
WUXIF

WuXi AppTec

$19.88 /

+ (+0.00%)

, ABBV

AbbVie

$117.11 /

+1.21 (+1.04%)

, AMGN

Amgen

$251.82 /

+3.19 (+1.28%)

, ALPMY

Astellas Pharma

$15.48 /

+0.09 (+0.58%)

, AZN

AstraZeneca

$57.47 /

+1.13 (+2.01%)

, BGNE

BeiGene

$344.38 /

+11.75 (+3.53%)

, BMY

Bristol-Myers

$66.98 /

+1.42 (+2.17%)

, GILD

Gilead

$69.35 /

+0.85 (+1.24%)

, GSK

GlaxoSmithKline

$39.04 /

+0.327049 (+0.84%)

, INCY

Incyte

$83.48 /

+1.76 (+2.15%)

, JAZZ

Jazz Pharmaceuticals

$178.65 /

+3.605 (+2.06%)

, LLY

Eli Lilly

$199.53 /

+3.07 (+1.56%)

, MRK

Merck

$79.66 /

+0.29 (+0.37%)

, NVS

Novartis

$87.93 /

+0.28 (+0.32%)

, NVCR

Novocure

$182.30 /

+5.62 (+3.18%)

, PFE

Pfizer

$40.13 /

+0.285 (+0.72%)

, SNY

Sanofi

$54.07 /

+1.18 (+2.23%)

, SGEN

Seagen

$155.48 /

+6.705 (+4.51%)

, TAK

Takeda Pharmaceutical

$17.32 /

+0.17 (+0.99%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on May 17-21.Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

SNY Sanofi
$54.07 /

+1.18 (+2.23%)

SGEN Seagen
$155.48 /

+6.705 (+4.51%)

PFE Pfizer
$40.13 /

+0.285 (+0.72%)

NVS Novartis
$87.93 /

+0.28 (+0.32%)

NVCR Novocure
$182.30 /

+5.62 (+3.18%)

MRK Merck
$79.66 /

+0.29 (+0.37%)

LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

JAZZ Jazz Pharmaceuticals
$178.65 /

+3.605 (+2.06%)

INCY Incyte
$83.48 /

+1.76 (+2.15%)

GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

GILD Gilead
$69.35 /

+0.85 (+1.24%)

BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

BGNE BeiGene
$344.38 /

+11.75 (+3.53%)

AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

AMGN Amgen
$251.82 /

+3.19 (+1.28%)

ALPMY Astellas Pharma
$15.48 /

+0.09 (+0.58%)

ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

WUXIF WuXi AppTec
$19.88 /

+ (+0.00%)

09/30/20 Goldman Sachs
WuXi AppTec reinstated with a Buy at Goldman Sachs
ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
AMGN Amgen
$251.82 /

+3.19 (+1.28%)

05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
ALPMY Astellas Pharma
$15.48 /

+0.09 (+0.58%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
BGNE BeiGene
$344.38 /

+11.75 (+3.53%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$69.35 /

+0.85 (+1.24%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
INCY Incyte
$83.48 /

+1.76 (+2.15%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
JAZZ Jazz Pharmaceuticals
$178.65 /

+3.605 (+2.06%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
MRK Merck
$79.66 /

+0.29 (+0.37%)

05/20/21
Fly Intel: Top five analyst downgrades
05/20/21 Argus
Merck downgraded to Hold at Argus ahead of Organon spinoff
05/20/21 Argus
Merck downgraded to Hold from Buy at Argus
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
NVS Novartis
$87.93 /

+0.28 (+0.32%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVCR Novocure
$182.30 /

+5.62 (+3.18%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
PFE Pfizer
$40.13 /

+0.285 (+0.72%)

05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
SNY Sanofi
$54.07 /

+1.18 (+2.23%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SGEN Seagen
$155.48 /

+6.705 (+4.51%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

SNY Sanofi
$54.07 /

+1.18 (+2.23%)

SGEN Seagen
$155.48 /

+6.705 (+4.51%)

PFE Pfizer
$40.13 /

+0.285 (+0.72%)

NVS Novartis
$87.93 /

+0.28 (+0.32%)

NVCR Novocure
$182.30 /

+5.62 (+3.18%)

MRK Merck
$79.66 /

+0.29 (+0.37%)

LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

JAZZ Jazz Pharmaceuticals
$178.65 /

+3.605 (+2.06%)

INCY Incyte
$83.48 /

+1.76 (+2.15%)

GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

GILD Gilead
$69.35 /

+0.85 (+1.24%)

BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

BGNE BeiGene
$344.38 /

+11.75 (+3.53%)

AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

AMGN Amgen
$251.82 /

+3.19 (+1.28%)

ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

  • 02
    Dec
TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

SNY Sanofi
$54.07 /

+1.18 (+2.23%)

PFE Pfizer
$40.13 /

+0.285 (+0.72%)

NVS Novartis
$87.93 /

+0.28 (+0.32%)

MRK Merck
$79.66 /

+0.29 (+0.37%)

LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

JAZZ Jazz Pharmaceuticals
$178.65 /

+3.605 (+2.06%)

INCY Incyte
$83.48 /

+1.76 (+2.15%)

GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

GILD Gilead
$69.35 /

+0.85 (+1.24%)

BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

AMGN Amgen
$251.82 /

+3.19 (+1.28%)

ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

SNY Sanofi
$54.07 /

+1.18 (+2.23%)

SGEN Seagen
$155.48 /

+6.705 (+4.51%)

PFE Pfizer
$40.13 /

+0.285 (+0.72%)

NVS Novartis
$87.93 /

+0.28 (+0.32%)

NVCR Novocure
$182.30 /

+5.62 (+3.18%)

MRK Merck
$79.66 /

+0.29 (+0.37%)

LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

JAZZ Jazz Pharmaceuticals
$178.65 /

+3.605 (+2.06%)

INCY Incyte
$83.48 /

+1.76 (+2.15%)

GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

GILD Gilead
$69.35 /

+0.85 (+1.24%)

BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

AMGN Amgen
$251.82 /

+3.19 (+1.28%)

ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

TAK Takeda Pharmaceutical
$17.32 /

+0.17 (+0.99%)

PFE Pfizer
$40.13 /

+0.285 (+0.72%)

MRK Merck
$79.66 /

+0.29 (+0.37%)

LLY Eli Lilly
$199.53 /

+3.07 (+1.56%)

INCY Incyte
$83.48 /

+1.76 (+2.15%)

GSK GlaxoSmithKline
$39.04 /

+0.327049 (+0.84%)

GILD Gilead
$69.35 /

+0.85 (+1.24%)

BMY Bristol-Myers
$66.98 /

+1.42 (+2.17%)

AZN AstraZeneca
$57.47 /

+1.13 (+2.01%)

AMGN Amgen
$251.82 /

+3.19 (+1.28%)

ABBV AbbVie
$117.11 /

+1.21 (+1.04%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
05/20/21
05/20
04:55
05/20/21
04:55
WUXIF

WuXi AppTec

$19.88 /

+ (+0.00%)

, ABBV

AbbVie

$115.90 /

-1.32 (-1.13%)

, AMGN

Amgen

$248.70 /

-2.13 (-0.85%)

, ALPMY

Astellas Pharma

$15.39 /

+0.04 (+0.26%)

, AZN

AstraZeneca

$56.34 /

+0.34 (+0.61%)

, BGNE

BeiGene

$335.13 /

-3.1 (-0.92%)

, BMY

Bristol-Myers

$65.57 /

-0.03 (-0.05%)

, GILD

Gilead

$68.51 /

-0.33 (-0.48%)

, GSK

GlaxoSmithKline

$38.71 /

-0.320049 (-0.82%)

, INCY

Incyte

$81.73 /

-0.12 (-0.15%)

, JAZZ

Jazz Pharmaceuticals

$175.19 /

-0.04 (-0.02%)

, LLY

Eli Lilly

$196.56 /

+1.97 (+1.01%)

, MRK

Merck

$79.37 /

-0.01 (-0.01%)

, NVS

Novartis

$87.68 /

-1.08 (-1.22%)

, NVCR

Novocure

$176.74 /

-3.775 (-2.09%)

, PFE

Pfizer

$39.84 /

-0.2 (-0.50%)

, SNY

Sanofi

$52.89 /

-0.5599 (-1.05%)

, SGEN

Seagen

$148.78 /

+0.385 (+0.26%)

, TAK

Takeda Pharmaceutical

$17.15 /

-0.09 (-0.52%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on May 17-21.Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

SNY Sanofi
$52.89 /

-0.5599 (-1.05%)

SGEN Seagen
$148.78 /

+0.385 (+0.26%)

PFE Pfizer
$39.84 /

-0.2 (-0.50%)

NVS Novartis
$87.68 /

-1.08 (-1.22%)

NVCR Novocure
$176.74 /

-3.775 (-2.09%)

MRK Merck
$79.37 /

-0.01 (-0.01%)

LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

JAZZ Jazz Pharmaceuticals
$175.19 /

-0.04 (-0.02%)

INCY Incyte
$81.73 /

-0.12 (-0.15%)

GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

GILD Gilead
$68.51 /

-0.33 (-0.48%)

BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

BGNE BeiGene
$335.13 /

-3.1 (-0.92%)

AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

AMGN Amgen
$248.70 /

-2.13 (-0.85%)

ALPMY Astellas Pharma
$15.39 /

+0.04 (+0.26%)

ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

WUXIF WuXi AppTec
$19.88 /

+ (+0.00%)

09/30/20 Goldman Sachs
WuXi AppTec reinstated with a Buy at Goldman Sachs
ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
AMGN Amgen
$248.70 /

-2.13 (-0.85%)

05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
ALPMY Astellas Pharma
$15.39 /

+0.04 (+0.26%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
BGNE BeiGene
$335.13 /

-3.1 (-0.92%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$68.51 /

-0.33 (-0.48%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
INCY Incyte
$81.73 /

-0.12 (-0.15%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
JAZZ Jazz Pharmaceuticals
$175.19 /

-0.04 (-0.02%)

05/19/21
Fly Intel: Top five analyst initiations
05/19/21 JPMorgan
Jazz Pharmaceuticals resumed with an Overweight at JPMorgan
05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
MRK Merck
$79.37 /

-0.01 (-0.01%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
NVS Novartis
$87.68 /

-1.08 (-1.22%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVCR Novocure
$176.74 /

-3.775 (-2.09%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
PFE Pfizer
$39.84 /

-0.2 (-0.50%)

05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
SNY Sanofi
$52.89 /

-0.5599 (-1.05%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SGEN Seagen
$148.78 /

+0.385 (+0.26%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

SNY Sanofi
$52.89 /

-0.5599 (-1.05%)

SGEN Seagen
$148.78 /

+0.385 (+0.26%)

PFE Pfizer
$39.84 /

-0.2 (-0.50%)

NVS Novartis
$87.68 /

-1.08 (-1.22%)

NVCR Novocure
$176.74 /

-3.775 (-2.09%)

MRK Merck
$79.37 /

-0.01 (-0.01%)

LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

JAZZ Jazz Pharmaceuticals
$175.19 /

-0.04 (-0.02%)

INCY Incyte
$81.73 /

-0.12 (-0.15%)

GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

GILD Gilead
$68.51 /

-0.33 (-0.48%)

BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

BGNE BeiGene
$335.13 /

-3.1 (-0.92%)

AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

AMGN Amgen
$248.70 /

-2.13 (-0.85%)

ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

  • 02
    Dec
TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

SNY Sanofi
$52.89 /

-0.5599 (-1.05%)

PFE Pfizer
$39.84 /

-0.2 (-0.50%)

NVS Novartis
$87.68 /

-1.08 (-1.22%)

MRK Merck
$79.37 /

-0.01 (-0.01%)

LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

JAZZ Jazz Pharmaceuticals
$175.19 /

-0.04 (-0.02%)

INCY Incyte
$81.73 /

-0.12 (-0.15%)

GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

GILD Gilead
$68.51 /

-0.33 (-0.48%)

BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

AMGN Amgen
$248.70 /

-2.13 (-0.85%)

ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

SNY Sanofi
$52.89 /

-0.5599 (-1.05%)

SGEN Seagen
$148.78 /

+0.385 (+0.26%)

PFE Pfizer
$39.84 /

-0.2 (-0.50%)

NVS Novartis
$87.68 /

-1.08 (-1.22%)

NVCR Novocure
$176.74 /

-3.775 (-2.09%)

MRK Merck
$79.37 /

-0.01 (-0.01%)

LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

JAZZ Jazz Pharmaceuticals
$175.19 /

-0.04 (-0.02%)

INCY Incyte
$81.73 /

-0.12 (-0.15%)

GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

GILD Gilead
$68.51 /

-0.33 (-0.48%)

BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

AMGN Amgen
$248.70 /

-2.13 (-0.85%)

ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

TAK Takeda Pharmaceutical
$17.15 /

-0.09 (-0.52%)

PFE Pfizer
$39.84 /

-0.2 (-0.50%)

MRK Merck
$79.37 /

-0.01 (-0.01%)

LLY Eli Lilly
$196.56 /

+1.97 (+1.01%)

INCY Incyte
$81.73 /

-0.12 (-0.15%)

GSK GlaxoSmithKline
$38.71 /

-0.320049 (-0.82%)

GILD Gilead
$68.51 /

-0.33 (-0.48%)

BMY Bristol-Myers
$65.57 /

-0.03 (-0.05%)

AZN AstraZeneca
$56.34 /

+0.34 (+0.61%)

AMGN Amgen
$248.70 /

-2.13 (-0.85%)

ABBV AbbVie
$115.90 /

-1.32 (-1.13%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
05/19/21
05/19
04:55
05/19/21
04:55
WUXIF

WuXi AppTec

$19.88 /

+ (+0.00%)

, ABBV

AbbVie

$117.22 /

+0.36 (+0.31%)

, AMGN

Amgen

$250.95 /

-1.36 (-0.54%)

, ALPMY

Astellas Pharma

$15.35 /

+0.01 (+0.07%)

, AZN

AstraZeneca

$56.00 /

+0.13 (+0.23%)

, BGNE

BeiGene

$338.09 /

+15.11 (+4.68%)

, BMY

Bristol-Myers

$65.60 /

+0.14 (+0.21%)

, GILD

Gilead

$68.84 /

-0.2498 (-0.36%)

, GSK

GlaxoSmithKline

$39.56 /

-0.025 (-0.06%)

, INCY

Incyte

$81.81 /

-0.42 (-0.51%)

, JAZZ

Jazz Pharmaceuticals

$175.18 /

-1.5 (-0.85%)

, LLY

Eli Lilly

$194.66 /

-0.89 (-0.46%)

, MRK

Merck

$79.38 /

-0.49 (-0.61%)

, NVS

Novartis

$88.68 /

+0.1301 (+0.15%)

, NVCR

Novocure

$180.42 /

+6.08 (+3.49%)

, PFE

Pfizer

$40.04 /

-0.075 (-0.19%)

, SNY

Sanofi

$53.45 /

-0.05 (-0.09%)

, SGEN

Seagen

$148.37 /

+0.43 (+0.29%)

, TAK

Takeda Pharmaceutical

$17.24 /

+0.025 (+0.15%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on May 17-21.Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

SNY Sanofi
$53.45 /

-0.05 (-0.09%)

SGEN Seagen
$148.37 /

+0.43 (+0.29%)

PFE Pfizer
$40.04 /

-0.075 (-0.19%)

NVS Novartis
$88.68 /

+0.1301 (+0.15%)

NVCR Novocure
$180.42 /

+6.08 (+3.49%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

JAZZ Jazz Pharmaceuticals
$175.18 /

-1.5 (-0.85%)

INCY Incyte
$81.81 /

-0.42 (-0.51%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GILD Gilead
$68.84 /

-0.2498 (-0.36%)

BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

BGNE BeiGene
$338.09 /

+15.11 (+4.68%)

AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

AMGN Amgen
$250.95 /

-1.36 (-0.54%)

ALPMY Astellas Pharma
$15.35 /

+0.01 (+0.07%)

ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

WUXIF WuXi AppTec
$19.88 /

+ (+0.00%)

09/30/20 Goldman Sachs
WuXi AppTec reinstated with a Buy at Goldman Sachs
ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
04/30/21 Piper Sandler
AbbVie price target raised to $124 from $120 at Piper Sandler
AMGN Amgen
$250.95 /

-1.36 (-0.54%)

05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
ALPMY Astellas Pharma
$15.35 /

+0.01 (+0.07%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
BGNE BeiGene
$338.09 /

+15.11 (+4.68%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$68.84 /

-0.2498 (-0.36%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
INCY Incyte
$81.81 /

-0.42 (-0.51%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
JAZZ Jazz Pharmaceuticals
$175.18 /

-1.5 (-0.85%)

05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
04/06/21 RBC Capital
Jazz Pharmaceuticals transferred with an Outperform at RBC Capital
LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
MRK Merck
$79.38 /

-0.49 (-0.61%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
NVS Novartis
$88.68 /

+0.1301 (+0.15%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVCR Novocure
$180.42 /

+6.08 (+3.49%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
PFE Pfizer
$40.04 /

-0.075 (-0.19%)

05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
SNY Sanofi
$53.45 /

-0.05 (-0.09%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SGEN Seagen
$148.37 /

+0.43 (+0.29%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

SNY Sanofi
$53.45 /

-0.05 (-0.09%)

SGEN Seagen
$148.37 /

+0.43 (+0.29%)

PFE Pfizer
$40.04 /

-0.075 (-0.19%)

NVS Novartis
$88.68 /

+0.1301 (+0.15%)

NVCR Novocure
$180.42 /

+6.08 (+3.49%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

JAZZ Jazz Pharmaceuticals
$175.18 /

-1.5 (-0.85%)

INCY Incyte
$81.81 /

-0.42 (-0.51%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GILD Gilead
$68.84 /

-0.2498 (-0.36%)

BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

BGNE BeiGene
$338.09 /

+15.11 (+4.68%)

AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

AMGN Amgen
$250.95 /

-1.36 (-0.54%)

ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

  • 02
    Dec
TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

SNY Sanofi
$53.45 /

-0.05 (-0.09%)

PFE Pfizer
$40.04 /

-0.075 (-0.19%)

NVS Novartis
$88.68 /

+0.1301 (+0.15%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

JAZZ Jazz Pharmaceuticals
$175.18 /

-1.5 (-0.85%)

INCY Incyte
$81.81 /

-0.42 (-0.51%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GILD Gilead
$68.84 /

-0.2498 (-0.36%)

BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

AMGN Amgen
$250.95 /

-1.36 (-0.54%)

ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

SNY Sanofi
$53.45 /

-0.05 (-0.09%)

SGEN Seagen
$148.37 /

+0.43 (+0.29%)

PFE Pfizer
$40.04 /

-0.075 (-0.19%)

NVS Novartis
$88.68 /

+0.1301 (+0.15%)

NVCR Novocure
$180.42 /

+6.08 (+3.49%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

JAZZ Jazz Pharmaceuticals
$175.18 /

-1.5 (-0.85%)

INCY Incyte
$81.81 /

-0.42 (-0.51%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GILD Gilead
$68.84 /

-0.2498 (-0.36%)

BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

AMGN Amgen
$250.95 /

-1.36 (-0.54%)

ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

TAK Takeda Pharmaceutical
$17.24 /

+0.025 (+0.15%)

PFE Pfizer
$40.04 /

-0.075 (-0.19%)

MRK Merck
$79.38 /

-0.49 (-0.61%)

LLY Eli Lilly
$194.66 /

-0.89 (-0.46%)

INCY Incyte
$81.81 /

-0.42 (-0.51%)

GSK GlaxoSmithKline
$39.56 /

-0.025 (-0.06%)

GILD Gilead
$68.84 /

-0.2498 (-0.36%)

BMY Bristol-Myers
$65.60 /

+0.14 (+0.21%)

AZN AstraZeneca
$56.00 /

+0.13 (+0.23%)

AMGN Amgen
$250.95 /

-1.36 (-0.54%)

ABBV AbbVie
$117.22 /

+0.36 (+0.31%)

Hot Stocks
Novocure receives FDA approval for LUNAR trial IDE supplement » 07:34
05/18/21
05/18
07:34
05/18/21
07:34
NVCR

Novocure

$174.85 /

-4.67 (-2.60%)

Novocure announced the…

Novocure announced the FDA has approved the company's Investigational Device Exemption, or IDE, supplement, reducing the enrollment requirement for its LUNAR trial to 276 patients with 12 months follow-up. LUNAR is a phase 3 pivotal trial testing the effectiveness of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone for patients with stage 4 NSCLC who progressed during or after platinum-based therapy. The IDE supplement incorporates recommended changes from the interim analysis of the LUNAR trial conducted by an independent data monitoring committee, or DMC. After review of the interim analysis report earlier this year, the DMC concluded that the LUNAR trial should continue with no evidence of increased systemic toxicity. The DMC also stated that it is likely unnecessary and possibly unethical for patients randomized to the control arm of the trial to continue accrual according to the original protocol. The DMC recommended a reduced sample size of approximately 276 patients with 12 months follow-up which it believes will provide sufficient overall power for both primary and secondary endpoints. The DMC recommended no other changes to the trial design. Novocure remains blinded to all data.

ShowHide Related Items >><<
NVCR Novocure
$174.85 /

-4.67 (-2.60%)

NVCR Novocure
$174.85 /

-4.67 (-2.60%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
NVCR Novocure
$174.85 /

-4.67 (-2.60%)

NVCR Novocure
$174.85 /

-4.67 (-2.60%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 04:55
05/18/21
05/18
04:55
05/18/21
04:55
WUXIF

WuXi AppTec

$19.88 /

+ (+0.00%)

, ABBV

AbbVie

$116.86 /

+0.44 (+0.38%)

, AMGN

Amgen

$252.39 /

+0.79 (+0.31%)

, ALPMY

Astellas Pharma

$15.34 /

+0.045 (+0.29%)

, AZN

AstraZeneca

$55.87 /

+0.63 (+1.14%)

, BGNE

BeiGene

$323.29 /

+3.28 (+1.02%)

, BMY

Bristol-Myers

$65.46 /

+0.58 (+0.89%)

, GILD

Gilead

$69.09 /

+0.54 (+0.79%)

, GSK

GlaxoSmithKline

$39.59 /

+0.49 (+1.25%)

, INCY

Incyte

$82.23 /

-0.49 (-0.59%)

, JAZZ

Jazz Pharmaceuticals

$176.68 /

-2.75 (-1.53%)

, LLY

Eli Lilly

$195.55 /

-0.8 (-0.41%)

, MRK

Merck

$79.87 /

+1.61 (+2.06%)

, NVS

Novartis

$88.55 /

-0.44 (-0.49%)

, NVCR

Novocure

$174.85 /

-4.67 (-2.60%)

, PFE

Pfizer

$40.12 /

+0.08 (+0.20%)

, SNY

Sanofi

$53.50 /

+0.82 (+1.56%)

, SGEN

Seagen

$147.90 /

+0.41 (+0.28%)

, TAK

Takeda Pharmaceutical

$17.22 /

+0.095 (+0.55%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on May 17-21.Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

SNY Sanofi
$53.50 /

+0.82 (+1.56%)

SGEN Seagen
$147.90 /

+0.41 (+0.28%)

PFE Pfizer
$40.12 /

+0.08 (+0.20%)

NVS Novartis
$88.55 /

-0.44 (-0.49%)

NVCR Novocure
$174.85 /

-4.67 (-2.60%)

MRK Merck
$79.87 /

+1.61 (+2.06%)

LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

JAZZ Jazz Pharmaceuticals
$176.68 /

-2.75 (-1.53%)

INCY Incyte
$82.23 /

-0.49 (-0.59%)

GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

GILD Gilead
$69.09 /

+0.54 (+0.79%)

BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

BGNE BeiGene
$323.29 /

+3.28 (+1.02%)

AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

AMGN Amgen
$252.39 /

+0.79 (+0.31%)

ALPMY Astellas Pharma
$15.34 /

+0.045 (+0.29%)

ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

WUXIF WuXi AppTec
$19.88 /

+ (+0.00%)

09/30/20 Goldman Sachs
WuXi AppTec reinstated with a Buy at Goldman Sachs
ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
04/30/21 Piper Sandler
AbbVie price target raised to $124 from $120 at Piper Sandler
AMGN Amgen
$252.39 /

+0.79 (+0.31%)

05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
ALPMY Astellas Pharma
$15.34 /

+0.045 (+0.29%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
BGNE BeiGene
$323.29 /

+3.28 (+1.02%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$69.09 /

+0.54 (+0.79%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
INCY Incyte
$82.23 /

-0.49 (-0.59%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
JAZZ Jazz Pharmaceuticals
$176.68 /

-2.75 (-1.53%)

05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
04/06/21 RBC Capital
Jazz Pharmaceuticals transferred with an Outperform at RBC Capital
LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
MRK Merck
$79.87 /

+1.61 (+2.06%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
NVS Novartis
$88.55 /

-0.44 (-0.49%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVCR Novocure
$174.85 /

-4.67 (-2.60%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
PFE Pfizer
$40.12 /

+0.08 (+0.20%)

05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
05/06/21
Fly Intel: Top five analyst downgrades
SNY Sanofi
$53.50 /

+0.82 (+1.56%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SGEN Seagen
$147.90 /

+0.41 (+0.28%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

SNY Sanofi
$53.50 /

+0.82 (+1.56%)

SGEN Seagen
$147.90 /

+0.41 (+0.28%)

PFE Pfizer
$40.12 /

+0.08 (+0.20%)

NVS Novartis
$88.55 /

-0.44 (-0.49%)

NVCR Novocure
$174.85 /

-4.67 (-2.60%)

MRK Merck
$79.87 /

+1.61 (+2.06%)

LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

JAZZ Jazz Pharmaceuticals
$176.68 /

-2.75 (-1.53%)

INCY Incyte
$82.23 /

-0.49 (-0.59%)

GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

GILD Gilead
$69.09 /

+0.54 (+0.79%)

BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

BGNE BeiGene
$323.29 /

+3.28 (+1.02%)

AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

AMGN Amgen
$252.39 /

+0.79 (+0.31%)

ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

  • 02
    Dec
TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

SNY Sanofi
$53.50 /

+0.82 (+1.56%)

PFE Pfizer
$40.12 /

+0.08 (+0.20%)

NVS Novartis
$88.55 /

-0.44 (-0.49%)

MRK Merck
$79.87 /

+1.61 (+2.06%)

LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

JAZZ Jazz Pharmaceuticals
$176.68 /

-2.75 (-1.53%)

INCY Incyte
$82.23 /

-0.49 (-0.59%)

GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

GILD Gilead
$69.09 /

+0.54 (+0.79%)

BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

AMGN Amgen
$252.39 /

+0.79 (+0.31%)

ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

SNY Sanofi
$53.50 /

+0.82 (+1.56%)

SGEN Seagen
$147.90 /

+0.41 (+0.28%)

PFE Pfizer
$40.12 /

+0.08 (+0.20%)

NVS Novartis
$88.55 /

-0.44 (-0.49%)

NVCR Novocure
$174.85 /

-4.67 (-2.60%)

MRK Merck
$79.87 /

+1.61 (+2.06%)

LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

JAZZ Jazz Pharmaceuticals
$176.68 /

-2.75 (-1.53%)

INCY Incyte
$82.23 /

-0.49 (-0.59%)

GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

GILD Gilead
$69.09 /

+0.54 (+0.79%)

BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

AMGN Amgen
$252.39 /

+0.79 (+0.31%)

ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

TAK Takeda Pharmaceutical
$17.22 /

+0.095 (+0.55%)

PFE Pfizer
$40.12 /

+0.08 (+0.20%)

MRK Merck
$79.87 /

+1.61 (+2.06%)

LLY Eli Lilly
$195.55 /

-0.8 (-0.41%)

INCY Incyte
$82.23 /

-0.49 (-0.59%)

GSK GlaxoSmithKline
$39.59 /

+0.49 (+1.25%)

GILD Gilead
$69.09 /

+0.54 (+0.79%)

BMY Bristol-Myers
$65.46 /

+0.58 (+0.89%)

AZN AstraZeneca
$55.87 /

+0.63 (+1.14%)

AMGN Amgen
$252.39 /

+0.79 (+0.31%)

ABBV AbbVie
$116.86 /

+0.44 (+0.38%)

Conference/Events
American Association for Cancer Research to hold a virtual meeting » 10:16
05/17/21
05/17
10:16
05/17/21
10:16
WUXIF

WuXi AppTec

$19.88 /

+ (+0.00%)

, ABBV

AbbVie

$117.13 /

+0.71 (+0.61%)

, AMGN

Amgen

$252.94 /

+1.34 (+0.53%)

, ALPMY

Astellas Pharma

$15.30 /

+0.035 (+0.23%)

, AZN

AstraZeneca

$55.69 /

+0.45 (+0.81%)

, BGNE

BeiGene

$325.12 /

+5.11 (+1.60%)

, BMY

Bristol-Myers

$65.44 /

+0.56 (+0.86%)

, GILD

Gilead

$69.33 /

+0.78 (+1.14%)

, GSK

GlaxoSmithKline

$39.54 /

+0.44 (+1.13%)

, INCY

Incyte

$82.77 /

+0.05 (+0.06%)

, JAZZ

Jazz Pharmaceuticals

$179.08 /

-0.35 (-0.20%)

, LLY

Eli Lilly

$199.26 /

+2.91 (+1.48%)

, MRK

Merck

$79.70 /

+1.44 (+1.84%)

, NVS

Novartis

$89.05 /

+0.06 (+0.07%)

, NVCR

Novocure

$176.87 /

-2.65 (-1.48%)

, PFE

Pfizer

$40.34 /

+0.3 (+0.75%)

, SNY

Sanofi

$53.32 /

+0.64 (+1.21%)

, SGEN

Seagen

$148.35 /

+0.86 (+0.58%)

, TAK

Takeda Pharmaceutical

$17.20 /

+0.08 (+0.47%)

AACR Virtual Annual…

AACR Virtual Annual Meeting 2021 will be held on May 17-21.Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

SNY Sanofi
$53.32 /

+0.64 (+1.21%)

SGEN Seagen
$148.35 /

+0.86 (+0.58%)

PFE Pfizer
$40.34 /

+0.3 (+0.75%)

NVS Novartis
$89.05 /

+0.06 (+0.07%)

NVCR Novocure
$176.87 /

-2.65 (-1.48%)

MRK Merck
$79.70 /

+1.44 (+1.84%)

LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

JAZZ Jazz Pharmaceuticals
$179.08 /

-0.35 (-0.20%)

INCY Incyte
$82.77 /

+0.05 (+0.06%)

GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

GILD Gilead
$69.33 /

+0.78 (+1.14%)

BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

BGNE BeiGene
$325.12 /

+5.11 (+1.60%)

AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

AMGN Amgen
$252.94 /

+1.34 (+0.53%)

ALPMY Astellas Pharma
$15.30 /

+0.035 (+0.23%)

ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

WUXIF WuXi AppTec
$19.88 /

+ (+0.00%)

09/30/20 Goldman Sachs
WuXi AppTec reinstated with a Buy at Goldman Sachs
ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
04/30/21 Piper Sandler
AbbVie price target raised to $124 from $120 at Piper Sandler
AMGN Amgen
$252.94 /

+1.34 (+0.53%)

05/03/21 Oppenheimer
Amgen price target lowered to $265 from $275 at Oppenheimer
04/28/21 Atlantic Equities
Amgen downgraded to Underweight from Neutral at Atlantic Equities
04/28/21 Credit Suisse
Amgen price target lowered to $259 from $265 at Credit Suisse
04/28/21 BMO Capital
Amgen price target lowered to $296 from $301 at BMO Capital
ALPMY Astellas Pharma
$15.30 /

+0.035 (+0.23%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
BGNE BeiGene
$325.12 /

+5.11 (+1.60%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

05/05/21 Wells Fargo
Wells sees 'limited impact' on Iovance's lifileucel from Keytruda/Yervoy data
04/30/21
Fly Intel: Top five analyst downgrades
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight on pipeline questions at Morgan Stanley
04/30/21 Morgan Stanley
Bristol-Myers downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$69.33 /

+0.78 (+1.14%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

05/11/21 UBS
GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
04/30/21 Deutsche Bank
GlaxoSmithKline price target raised to 1,200 GBp at Deutsche Bank
04/20/21 Morgan Stanley
GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley
04/20/21 UBS
GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS
INCY Incyte
$82.77 /

+0.05 (+0.06%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
JAZZ Jazz Pharmaceuticals
$179.08 /

-0.35 (-0.20%)

05/17/21 H.C. Wainwright
Jazz Pharmaceuticals price target raised to $212 from $207 at H.C. Wainwright
04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
04/06/21 RBC Capital
Jazz Pharmaceuticals transferred with an Outperform at RBC Capital
LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
MRK Merck
$79.70 /

+1.44 (+1.84%)

05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
04/20/21 Citi
GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
NVS Novartis
$89.05 /

+0.06 (+0.07%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVCR Novocure
$176.87 /

-2.65 (-1.48%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
PFE Pfizer
$40.34 /

+0.3 (+0.75%)

05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
05/11/21 SVB Leerink
BioNTech price target raised to $159 from $118 at SVB Leerink
05/10/21 Morgan Stanley
Pfizer price target raised to $42 from $38 at Morgan Stanley
05/06/21
Fly Intel: Top five analyst downgrades
SNY Sanofi
$53.32 /

+0.64 (+1.21%)

04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
SGEN Seagen
$148.35 /

+0.86 (+0.58%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

SNY Sanofi
$53.32 /

+0.64 (+1.21%)

SGEN Seagen
$148.35 /

+0.86 (+0.58%)

PFE Pfizer
$40.34 /

+0.3 (+0.75%)

NVS Novartis
$89.05 /

+0.06 (+0.07%)

NVCR Novocure
$176.87 /

-2.65 (-1.48%)

MRK Merck
$79.70 /

+1.44 (+1.84%)

LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

JAZZ Jazz Pharmaceuticals
$179.08 /

-0.35 (-0.20%)

INCY Incyte
$82.77 /

+0.05 (+0.06%)

GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

GILD Gilead
$69.33 /

+0.78 (+1.14%)

BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

BGNE BeiGene
$325.12 /

+5.11 (+1.60%)

AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

AMGN Amgen
$252.94 /

+1.34 (+0.53%)

ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

  • 02
    Dec
TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

SNY Sanofi
$53.32 /

+0.64 (+1.21%)

PFE Pfizer
$40.34 /

+0.3 (+0.75%)

NVS Novartis
$89.05 /

+0.06 (+0.07%)

MRK Merck
$79.70 /

+1.44 (+1.84%)

LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

JAZZ Jazz Pharmaceuticals
$179.08 /

-0.35 (-0.20%)

INCY Incyte
$82.77 /

+0.05 (+0.06%)

GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

GILD Gilead
$69.33 /

+0.78 (+1.14%)

BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

AMGN Amgen
$252.94 /

+1.34 (+0.53%)

ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

SNY Sanofi
$53.32 /

+0.64 (+1.21%)

SGEN Seagen
$148.35 /

+0.86 (+0.58%)

PFE Pfizer
$40.34 /

+0.3 (+0.75%)

NVS Novartis
$89.05 /

+0.06 (+0.07%)

NVCR Novocure
$176.87 /

-2.65 (-1.48%)

MRK Merck
$79.70 /

+1.44 (+1.84%)

LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

JAZZ Jazz Pharmaceuticals
$179.08 /

-0.35 (-0.20%)

INCY Incyte
$82.77 /

+0.05 (+0.06%)

GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

GILD Gilead
$69.33 /

+0.78 (+1.14%)

BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

AMGN Amgen
$252.94 /

+1.34 (+0.53%)

ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

TAK Takeda Pharmaceutical
$17.20 /

+0.08 (+0.47%)

PFE Pfizer
$40.34 /

+0.3 (+0.75%)

MRK Merck
$79.70 /

+1.44 (+1.84%)

LLY Eli Lilly
$199.26 /

+2.91 (+1.48%)

INCY Incyte
$82.77 /

+0.05 (+0.06%)

GSK GlaxoSmithKline
$39.54 /

+0.44 (+1.13%)

GILD Gilead
$69.33 /

+0.78 (+1.14%)

BMY Bristol-Myers
$65.44 /

+0.56 (+0.86%)

AZN AstraZeneca
$55.69 /

+0.45 (+0.81%)

AMGN Amgen
$252.94 /

+1.34 (+0.53%)

ABBV AbbVie
$117.13 /

+0.71 (+0.61%)

Earnings
Novocure reports Q1 EPS (4c), consensus 2c » 06:11
04/29/21
04/29
06:11
04/29/21
06:11
NVCR

Novocure

$205.50 /

-7 (-3.29%)

Reports Q1 revenue…

Reports Q1 revenue $134.7M, consensus $139.36M. "Over the last several months, we have made progress across multiple clinical development programs intended to determine Tumor Treating Fields' optimal use," said Executive Chairman William Doyle. "We continued to increase our understanding of the potential benefits of Tumor Treating Fields when used together with immunotherapies and continued to enroll patients in five late-stage clinical trials in multiple solid tumor types. The accelerated interim analysis of the LUNAR trial and the upcoming HEPANOVA data presentation represent the beginning of what we expect to be an exciting few years of data readouts from our pipeline." "Our track record of consistent execution and financial strength continued in Q1," added CEO Asaf Danziger. "We generated $135M in net revenues with an 80% gross margin, and we invested $46M in research and development intended to fuel future growth. With 3,454 active patients on therapy at the end of the quarter, we have treated nearly 20,000 patients globally, to date."

ShowHide Related Items >><<
NVCR Novocure
$205.50 /

-7 (-3.29%)

NVCR Novocure
$205.50 /

-7 (-3.29%)

04/19/21 Truist
Novocure price target raised to $142 from $132 at Truist
04/14/21
Fly Intel: Top five analyst downgrades
04/14/21 Northland
Novocure price target raised to $250 from $200 at Northland
04/14/21 Wedbush
Novocure downgraded to Underperform at Wedbush after LUNAR update
NVCR Novocure
$205.50 /

-7 (-3.29%)

NVCR Novocure
$205.50 /

-7 (-3.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.